# Adoptive Therapy Using Antigen-Specific CD4 T-Cells

> **NCT02210104** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Melanoma
- Sarcoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** CD4+ T cells

## Key facts

- **NCT ID:** NCT02210104
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-12
- **Primary completion:** 2019-12
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Issues with tetramer staining
- **Last updated:** 2017-07-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02210104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02210104, "Adoptive Therapy Using Antigen-Specific CD4 T-Cells". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02210104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*